Most people start weight-loss medication with a target weight in mind and an unexamined assumption that treatment ends when they reach it. The evidence does not support that assumption, and it is better to confront it at the start than at month nine.
What Happens When You Stop
These medicines work by altering appetite signalling while you take them. They do not permanently reset anything. When treatment stops, appetite regulation returns to roughly where it was, and weight is commonly regained over the following months.
This is not a failure of willpower and it is not unusual. It is the expected consequence of removing a treatment that was doing active work.
The framing that fits the evidence is closer to how blood pressure medication is understood: it manages a condition while it is taken. Nobody expects blood pressure to stay low after stopping an antihypertensive.
What This Means Financially
If treatment is potentially long-term, then the number that matters is not the cost of a six-month course. It is the cost per year, indefinitely, at whatever maintenance dose you settle on.
That changes which provider is right for you. Flat-rate providers who look expensive at the starting dose can be substantially cheaper across years of maintenance at a higher strength. It also makes it worth re-checking prices annually rather than choosing once.
What the Options Actually Are
Continuing at a maintenance dose
The approach best supported by the evidence for sustaining weight loss. Some people stay on a lower dose than their peak.
Stopping deliberately, with a plan
Reasonable if you understand the likely trajectory and have support in place for diet, activity and monitoring. Some regain is likely; how much varies.
Stopping because of cost or side effects
Common, and worth discussing rather than doing silently. There may be a cheaper provider, a lower maintenance dose, or a different medicine that suits you better.
NHS transfer
If you become eligible for NHS treatment, that changes the economics entirely. Worth checking periodically as the phased rollout widens.
The NHS Rollout Complicates This
NHS access to tirzepatide is being released in phases over years, and commissioning guidance frames the early period as one with review points rather than an open-ended commitment. If you are on NHS treatment, ask what the arrangements are for continuation and review — do not assume indefinite supply.
What to Ask Your Prescriber
- What is the plan if I reach my target weight?
- Is a lower maintenance dose an option for me?
- What happens if I stop — what should I expect, and over what timescale?
- How will we review whether this is still the right treatment?
A provider that has no answer to the first question is selling you months, not managing a condition.
The Part That Does Persist
Habits built during treatment — the way you eat, how much you move, the relationship you have with food — do not vanish when the medicine stops. They are not sufficient to hold all of the loss for most people, and it is unfair to pretend otherwise. But they are the part of the work that remains yours, and the people who do best after stopping are generally the ones who used the treatment period to build them.